•  
  •  
  •  
  •  

2025-12-25 08:34:15

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepak Mining Solutions Ltd to acquire 100% in Explosives Manufacturer
  • BharatRohan Airborne Innovations secures DGCA Type Certification for 'Pravir-X6', Advancing Sustainable Farm Mechanization
  • Karnataka HC sets aside IT assessment order with demand of Rs. 779.56 Mn against Aequs Limited
  • Silicon Rental Solutions Ltd receives order from Techfruits Solutions Pvt Ltd
  • Royal Orchid Hotels Strengthens Central India Portfolio with New Signing in Gwalior, Madhya Pradesh

Keywords Selected:  AjantaPharma

Stock Report

  • Biocon Ltd signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries
  • Ajanta signs in-licensing agreement with Biocon for marketing Semaglutide in 26 countries
  • Ajanta Pharma Ltd consolidated Q2FY26 PAT up at Rs. 260.19 crores
  • Ajanta Pharma Ltd consolidated Q1FY26 PAT up at Rs. 255.34 crores
  • Ajanta Pharma Ltd's consolidated profit slips QoQ to Rs. 225.26 crores
  • Ajanta Pharma Ltd's consolidated PAT for Q1 FY2025 jumps to Rs. 245.77 crores
  • Ajanta Pharma Ltd approves buy back of 10,28,881 shares through tender offer
  • Ajanta Pharma Ltd reports Rs. 202.72 crores consolidated PAT in Q4 FY2023-24
  • Ajanta Pharma Ltd posts consolidated Q3FY24 net profit of Rs. 210.03 crores
  • Ajanta Pharma Ltd posts Rs. 195.30 crores consolidated PAT in Q2FY24
  • Ajanta Pharma Ltd receives final approval from US FDA for Topiramate Extended Release Capsules
  • Ajanta Pharma Ltd approves 1st interim dividend of Rs. 25
  • Ajanta Pharma's Q1 FY24 consolidated net profit soars to Rs. 208.12 crores
  • USFDA inspects Ajanta Pharma Ltd's Formulation facility at Dahej
  • Ajanta pharma Ltd reports lower consolidated PAT of Rs. 122.25 crores in Q4FY23
  • Ajanta Pharma announces buyback of equity shares of Rs. 389 crore
  • Ajanta Pharma Ltd consolidated Q3 FY2022-23 net profit falls to Rs. 134.51 crores
  • Ajanta Pharma Ltd consolidated Q2 FY2022-23 net profit lower at Rs. 156.60 crores
  • Ajanta Pharma awarded 'India's Best Managed Companies' by Deloitte
  • Ajanta Pharma Ltd gets Form 483 with 2 procedural observations for Dahej Formulation facility
  • Ajanta Pharma reports rise in Q1FY23 consolidated PAT to Rs. 174.62 crores
  • Ajanta Pharma Ltd allots 4,27,08,385 bonus shares
  • Ajanta Pharma Ltd board approves 1:2 bonus issue
  • Ajanta Pharma consolidated Q4 FY2021-22 net profit lower at Rs. 151.21 crores

Latest Post

  • Deepak Mining Solutions Ltd to acquire 100% in Explosives Manufacturer
  • BharatRohan Airborne Innovations secures DGCA Type Certification for 'Pravir-X6', Advancing Sustainable Farm Mechanization
  • Karnataka HC sets aside IT assessment order with demand of Rs. 779.56 Mn against Aequs Limited
  • Silicon Rental Solutions Ltd receives order from Techfruits Solutions Pvt Ltd
  • Royal Orchid Hotels Strengthens Central India Portfolio with New Signing in Gwalior, Madhya Pradesh


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024